Clinical Proteomics in the Mann Group

The main research focus of the Clinical Proteomics Group headed by Professor Matthias Mann is to apply mass spectrometry (MS) based proteomics to understand human health and disease. The study of the proteome could lead to the improvement of patient diagnosis and stratification, and possibly to prevent diseases such as metabolic disorders and cancer. To this end, the lab is developing and applying cutting-edge MS-based proteomics techniques; an area in which the Mann Group is world-leading.

The Mann Group undertakes ambitious research projects involving proteomics of archived tissue specimens and body fluids for patient phenotyping. One goal is to establish robust, high-throughput proteome profiling pipelines for these patient materials, allowing for the proteomic interrogation of large clinical cohorts. The group’s overarching aim is to identify protein markers for early detection of diseases such diabetes and cancer, to improve diagnosis and help to develop individualized therapies.

 

 

 

 

 

 

 

 

 

Streamlined proteomic profiling of archived biobank tissues
We developed and applied a streamlined workflow for in-depth proteomic profiling of large clinical cohorts of formalin-fixed and paraffin-embedded (FFPE) tissues. Our workflow is simple, robust and universally applicable.

A streamlined mass spectrometry–based proteomics workflow for large‐scale FFPE tissue analysis - Coscia and Doll et al., The Journal of Pathology, 2020

Plasma proteome profiling in non-alcoholic fatty liver disease.
We employed Plasma Proteome Profiling augmented by a novel mass spectrometry acquisition method – “Boxcar” to identify potential biomarkers of non-alcoholic fatty liver disease (NAFLD) in human cohorts. We identified PIGR and ALDOB, among other four proteins significantly associated with NAFLD as well as a panel of five proteins correlating with four classic liver enzymes. A mouse model recapitulated many of the changes seen in human cohorts.

Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease – Niu and Geyer et al., Mol Syst Biol, 2019

Ovarian cancer biomarker discovered.
Integrative proteomic analysis in clinical tumor samples identifies a platinum sensitivity regulator and immunotherapy target for ovarian cancer and illustrates the clinical potential of cancer proteomics.

Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer - Coscia et al., Cell, 2018

Mass-spectrometric exploration of proteome structure and function
Recent advances in mass spectrometry-based proteomics now enable the investigation of nearly complete proteomes and has evolved into the method of choice for the identification and quantitation of proteins as well as their site-specific posttranslational modifications.

Ruedi Aebersold and Matthias Mann, Nature, 2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Group Leader

Matthias Mann
Professor, Research Director
Email

Matthias Mann

Staff list

Name Title Phone E-mail
Andreas Mund Associate Professor +4535325069 E-mail
Annelaura Bach Nielsen Postdoc +4535334474 E-mail
Beatrice Dyring-Andersen Associate Professor +4535337436 E-mail
Elena Krismer Research Assistant   E-mail
Filip Oskar Mundt Postdoc +4535332882 E-mail
Frederik Post PhD Fellow +4535324666 E-mail
Juanjuan Wang Postdoc +4535329767 E-mail
Kira Petzold Laboratory Technician +4535332871 E-mail
Lili Niu Postdoc +4535331177 E-mail
Lylia Drici Research Consultant +4535334900 E-mail
Matthias Mann Professor, Head of Research   E-mail
Maximilian Strauss Assistant Professor +4535326217 E-mail
Michael Martin Richter External, Ph.d Student +4522154336 E-mail
Nicolai Jacob Wewer Albrechtsen Associate Professor +4535330485 E-mail
Sasha Alexandra Sampson Kjeldsen PhD Fellow   E-mail
Sonja Kabatnik PhD Fellow +4535321204 E-mail
Xiang Zheng Postdoc +4535331821 E-mail